Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Virus or component thereof
Reexamination Certificate
2007-09-04
2007-09-04
Campbell, Bruce R. (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Virus or component thereof
C435S456000, C435S235100
Reexamination Certificate
active
10866505
ABSTRACT:
The present invention relates to the identification of bovine adenovirus sequence(s) essential for encapsidation and E1 transcriptional control regions. The present invention provides adenovirus expression systems, host cells and compositions comprising adenovirus vectors which comprise one or more BAV sequence(s) essential for encapsidation, as well as helper virus which express BAV sequences essential for encapsidation. The present invention also provides helper vectors comprising a BAV sequence essential for encapsidation which is used in a helper virus for propagating recombinant adenovirus. The present invention also provides adenovirus expression systems, host cells and compositions comprising adenovirus vectors which comprise modifications in BAV E1 transcriptional control regions. The present invention also provides methods for making adenovirus vectors comprising BAV sequence(s) essential for encapsidation as well as modifications in BAV E1 transcriptional control regions.
REFERENCES:
patent: 5820868 (1998-10-01), Mittal et al.
patent: 6001591 (1999-12-01), Mittal et al.
patent: 6086890 (2000-07-01), Mittal et al.
patent: 6319716 (2001-11-01), Tikoo et al.
patent: 6458586 (2002-10-01), Tikoo et al.
patent: 6479290 (2002-11-01), Mehtali et al.
patent: 0 259 149 (1988-03-01), None
patent: WO-2004/108939 (2004-12-01), None
Bowie et al., “Deciphering the message in protein sequences: tolerance to amino acid substitutions,” Science vol. 247:1306-1310 (1990).□□.
Reddy et al., “Replication-Defective Bovine Adenovirus type 3 as an Expression Vector,” Journal of Virology, Nov. 1999, pp. 9137-9144.
Reddy et al., “Nucleotide Sequence Genome Organization, and Transcription Map of Bovine Adenovirus Type 3,” Journal of Virology, Feb. 1998, pp. 1394-1402.
Russell, W.C. “Update on Adenovirus and its Vectors,” J. Gen. Virol. 81(11):2573-2604 (2000).
Ausubel, F.M. et al. eds. (1987).Current Protocols in Molecular Biology, Supp. 30, Section 7.7.18, Table 7.7.1, two pages.
Babiss, L.E. et al. (Feb. 1991). “Promoter of the Adenovirus Polypeptide IX Gene: Similarity to E1B and Inactivation by Substitution of the Simian Virus 40 TATA Element,”J. Virol.65(2):598-605.
Bartha, A. (1969). “Proposal For Subgrouping of Bovine Adenoviruses,”Acta. Vet. Acad. Sci. Hung19(3):319-321.
Baxi, M.K. et al. (1998). “Characterization of Bovine Adenovirus Type 3 Early Region 2B,”Virus Genes16(3):313-316.
Baxi, M.K. et al. (1999). “Transcription Map and Expression of Bovine Herpesvirus-1 Glycoprotein D in Early Region 4 of Bovine Adenovirus-3,”Virology261:143-152.
Berk, A.J. et al. (Aug. 1979). “Pre-Early Adenovirus 5 Gene Product Regulates Synthesis of Early Viral Messenger RNAs,”Cell17:935-944.
Bos, J.L. et al. (1983). “The E1b Promoter of Ad12 in Mouse L tk- Cells Is Activated by Adenovirus Region E1a,”EMBO J.2(1):73-76.
Braun, R.P. et al. (Sep. 15, 1988). “Immunogenic Duplex Nucleic Acids are Nuclease Resistant,”The Journal of Immunology141(6):2084-2089.
Brennan, S. et al. (1990). “Embryonic Transcriptional Activation of aXenopusCytoskeletal Actin Gene Does Not Require a Serum Response Element,”Roux's Arch. Dev. Biol. 199:89-96.
Chartier, C. et al. (Jul. 1996). “Efficient Generation of Recombinant Adenovirus Vectors by Homologous Recombination inEscherichia coli,” J. Virol. 70(7):4805-4810.
Chaturvedi, S. et al. (1996). “Stabilization of Triple-Stranded Oligonucleotide Complexes: Use of Probes Containing Alternating Phosphodiester and Stereo-Uniform Cationic Phosphoramidate Linkages,”Nucleic Acid Res. 24(12):2318-2323.
Daniell, E. (Aug. 1976). “Genome Structure of Incomplete Particles of Adenovirus,”J. Virol. 19(2):685-708.
Darbyshire, J.H. et al. (1965). “A New Adenovirus Serotype of Bovine Origin,”J. Comp. Pathol. 75:327-330.
D'Halluin, J.C. (1995). “Virus Assembly” InCurr. Top. Microbiol. ImmunolSpringer-Verlag. 199:47-66.
D'Halluin, J-C. et al. (May 1978). “Adenovirus Type 2 Assembly Analyzed by Reversible Cross-Linking of Labile Intermediates,”J. Virol. 26(2):357-363.
D'Halluin, J-C. et al. (May 1978). “Temperature-Sensitive Mutant of Adenovirus Type 2 Blocked in Virion Assemby: Accumulation of Light Intermediate Particles,”J. Virol. 26(2):344-356.
D'Halluin, J-C. et al. (Jan. 1980). “Morphogenesis of Human Adenovirus Type 2 Studied with Fiber- and Fiber and Penton Base-Defective Temperature-Sensitive Mutants,”J. Virol. 33(1):88-99.
Edvardsson, B. et al. (Aug. 1976). “Intermediates in Adenovirus Assembly,”J. Virol. 19(2):533-547.
Edvardsson, B. et al. (Feb. 1978). “Assembly Intermediates Among Adenovirus Type 5 Temperature-Sensitive Mutants,”J. Virol. 25(2):641-651.
Fallaux, F.J. et al. (Sep. 1, 1998). “New Helper Cells and Matched Early Region 1-Deleted Adenovirus Vectors Prevent Generation of Replication-Competent Adenoviruses,”Human Gene Therapy9:1909-1917.
GenBank Accession No. AF030154, created Oct. 20, 2000, located at <http://www.ncbi.nlm.nih.gov/entrez.viewer.fcgi?db=nucleotide&val=2935210> last visited on Nov. 5, 2004, 16 pages.
GenBank Accession No. AF036092, created on Feb. 17, 2004, located at <http://www.ncbi.nlm.nih.gov/entrez.viewer.fcgi?db=nucleotide&val=34223996> last visited on Nov. 5, 2004, 17 pages.
GenBank Accession No. AF252854, created on Aug. 15, 2000, located at <http://www.ncbi.nlm.nih.gov/entrez.viewer.fcgi?db=nucleotide&val=9802268> last visited on Nov. 5, 2004, 12 pages.
GenBank Accession No. J01917, created on Mar. 14, 1996, located at <http://www.ncbi.nlm.nih.gov/entrez.viewer.fcgi?db=nucleotide&val=209811> last visited on Nov. 5, 2004, 34 pages.
GenBank Accession No. M73260, created Apr. 8, 1996, located at <http://www . . . /query.fcgi?cmd=Retrieve&db=Nucleotide&list—uids=209842&dopt=GenBank . . . > last visited on Oct. 26, 2000, 12 pages.
GenBank Accession No. U77082, created Dec. 14, 1996, located at <http://www.ncbi.nlm.nih.gov/entrez.viewer.fcgi?db=nucleotide&val=1732265> last visited on Nov. 5, 2004, 16 pages.
Gräble, M. et al. (May 1990). “Adenovirus Type 5 Packaging Domain Is Composed of a Repeated Element That Is Functionally Redundant,”Journal of Virology64(5):2047-2056.
Gräble, M. et al. (Feb. 1992). “cisandtransRequirements for the Selective Packaging of Adenovirus Type 5 DNA,”J. Virol. 66(2):723-731.
Graham, F.L. et al. (1977). “Characteristics of a Human Cell Line Transformed by DNA from Human Adenovirus Type 5,”J. Gen. Virol. 36:59-74.
Grand, R.J.A. et al. (1987). “The Structure and Functions of the Adenovirus Early Region 1 Proteins,”Biochem. J. 241:25-38.
Gustin, K.E. et al. (Oct. 1998). “Encapsidation of Viral DNA Requires the Adenovirus L1 52/55-Kilodalton Protein,”J. Virol. 72(10):7860-7870.
Hammarskjöld, M-L. et al. (Jul. 1980). “Encapsidation of Adenovirus 16 DNA Is Directed by a Small DNA Sequence at the Left End of the Genome,”Cell20:787-795.
Hampsey, M. et al. (Jun. 1998). “Molecular Genetics of the RNA Polymerase II General Transcriptional Machinery,”Microbiol. Mol. Biol. Rev. 62(2):465-503.
Hatfield, L. et al. (1991). “Redundant Elements in the Adenovirus Type 5 Inverted Terminal Repeat Promote Bidirectional Transcription in Vitro and Are Important for Virus Growth in Vivo,”Virology184:265-276.
Hatfield, L. et al. (Jul. 1993). “The NFIII/OCT-1 Binding Site Stimulates Adenovirus DNA Repliction In Vivo and Is Functionally Redundant with Adjacent Sequences,”J. Virol. 67(7):3931-3939.
Hearing, P. et al. (Jul. 1983). “The Adenovirus Type 5 E1A Transcriptional Control Region Contains a Duplicated Enhancer Element,”Cell33:695-703.
Hearing, P. et al. (Apr. 25, 19
Tikoo Suresh K.
Xing Li
Campbell Bruce R.
Morrison & Foerster / LLP
Salvoza M. Franco
University of Saskatchewan
LandOfFree
BAV packaging regions and E1 transcriptional control regions does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with BAV packaging regions and E1 transcriptional control regions, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and BAV packaging regions and E1 transcriptional control regions will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3739218